

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Linezolid for Oral Suspension (5ml:100mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation.

Linezolid for Oral Suspension is a suspension in oral dosage form. The Group was the first in obtaining such approval for the PRC entities, and has previously obtained the production approvals for Linezolid bulk drug and injections. Linezolid for Oral Suspension can be used in newborn, child and adult patients, and is mainly used in the treatment of hospital-acquired pneumonia, community-acquired pneumonia, skin and soft tissue infections and vancomycin-resistant Enterococcus faecium infections which are caused by susceptible strains of specific microorganisms.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 23 April 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.